{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Triple negative breast cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"Microsatellite-instability high colorectal cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"Gastric cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Hepatocellular carcinoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"title":"Melanoma - immune checkpoint-naïve"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Non-small cell lung cancer (NSCLC) (tumor proportion score (TPS) < 50% or indeterminate)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"NSCLC programmed cell death ligand (PD-L1) low negative (TPS < 50%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Ovarian cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Renal cell carcinoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Squamous cell carcinoma of the head and neck"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Transitional carcinoma of the genitourinary (GU) tract"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Diffuse large B-cell lymphoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Primary Refractory Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Relapsed Melanoma"}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"}],"units":"Participants"}],"description":"ORR was percentage of participants with best overall response \\[complete response (CR) or partial response (PR)\\], per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"Epacadostat 100 mg tablet orally BID in combination with pembrolizumab 200 mg intravenously every 3 weeks (Q3W).","id":"OG000","title":"Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W"}],"paramType":"NUMBER","populationDescription":"The efficacy evaluable population included all participants enrolled in the study who received at least 1 dose of study drug (epacadostat or pembrolizumab). Number analyzed indicated participants analyzed in the respective tumor type.","reportingStatus":"POSTED","timeFrame":"Approximately 54 months","title":"Phase 2: Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}